ReviewCurrent pharmaceutical design2026
Exosomes in Osteoarthritis: Emerging Roles in Pathogenesis, Diagnosis, and Therapeutic Potential.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a leading cause of chronic pain and disability, particularly among the elderly. Despite its high global prevalence, the underlying mechanisms of OA are still not fully understood, and current treatments are largely limited to symptomatic relief. Exosomes, small extracellular vesicles involved in cell-to-cell communication, have recently gained attention for their diagnostic and therapeutic potential in OA. In particular, exosomes derived from Mesenchymal Stem Cells (MSCs) can modulate chondrocyte proliferation, apoptosis, autophagy, and inflammation. Emerging evidence also highlights the role of exosomal non-coding RNAs (ncRNAs), including miRNAs, lncRNAs, and circRNAs, in regulating cartilage degradation and subchondral bone remodeling. This review offers a comprehensive synthesis of current knowledge on the role of exosomes in OA, with a unique focus on their dual function as biomarkers and therapeutic tools. We further highlight the promise of exosome-based Drug Delivery Systems (DDSs) and propose future directions for integrating exosome technologies into OA treatment strategies. This work emphasizes the translational potential of exosomes as disease-modifying agents and regenerative tools in osteoarthritis.
Indexed as
Identifiers
41691692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.